secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivani Medical, Inc. (VANI)
CIK:        0001266806
Form:       8-K
Filed at:   2024-09-26T23:59:59+00:00
Accession:  0001753926-24-001628
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivani Medical gets Australian approval to start first-in-human GLP-1 implant trial LIBERATE-1
--------------------------------------------------------------------------------

- Approval from Bellberry HREC and TGA acknowledgement for LIBERATE-1 trial in obese/overweight subjects.
- Trial will evaluate safety, tolerability, and PK of exenatide NanoPortal implant in 24 participants.
- Preclinical data suggests comparable efficacy to semaglutide with twice-yearly dosing.
- Enrollment expected Q4 2024; data projected in 2025; Australian R&D incentives may defray costs.
- Data intended to support regulatory submissions in the US and other geographies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1266806/000175392624001628/0001753926-24-001628-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1266806/000175392624001628/vani-20240926.htm
  HTML page:      https://secwatch.observer/filing/0001753926-24-001628

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer